


# Pocket Reference to Early Rheumatoid Arthritis

Paul Emery



## Pocket Reference to Early Rheumatoid Arthritis

# Pocket Reference to Early Rheumatoid Arthritis

**Paul Emery**

arc Professor of Rheumatology

Academic Unit of Musculoskeletal Disease, University of Leeds,  
Leeds Teaching Hospitals Trust, UK

Published by Springer Healthcare, 236 Gray's Inn Road, London, WC1X 8HB, UK  
www.springerhealthcare.com

©2011 Springer Healthcare Ltd, a part of Springer Science+Business Media

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder.

British Library Cataloguing-in-Publication Data.

A catalogue record for this book is available from the British Library.

ISBN 978 1 85873 448 4

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher nor the authors can be held responsible for errors or for any consequences arising from the use of the information contained herein. Any product mentioned in this publication should be used in accordance with the prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

Commissioning editor: Dinah Alam  
Project editors: Hannah Cole and Alison Whitehouse  
Designers: Joe Harvey and Taymoor Fouladi  
Production: Marina Maher  
Printed in Great Britain by Latimer Trend & Company Ltd.

# Contents

## Author biography

<b>1</b>	<b>Rheumatoid arthritis: an overview</b>	<b>1</b>
	Incidence	1
	Aetiology and pathophysiology	2
	Socioeconomic burden of rheumatoid arthritis	4
<b>2</b>	<b>Diagnosis of rheumatoid arthritis</b>	<b>7</b>
	Typical clinical presentation	7
	Diagnostic criteria	9
	Differential diagnosis	9
	EULAR recommendations for differential diagnosis	10
	Diagnostic tests and evaluation of likelihood of progression	11
<b>3</b>	<b>The need for early diagnosis and intervention in rheumatoid arthritis</b>	<b>15</b>
	Undifferentiated and early arthritis	15
	The problems of early detection	16
	Evidence from clinical trials to support early intervention	19
	Aggressive treatment in early arthritis	22
<b>4</b>	<b>Treatment of rheumatoid arthritis</b>	<b>25</b>
	Goals of therapy	25
	The importance of treatment to target	25
	An overview of available medications	27
	NSAIDs and COX-2 inhibitors	27
	Corticosteroids	27
	DMARDs	28
	Biologic agents	30
	Conservative vs aggressive treatment approaches	39
	Overview of safety and tolerability profiles	39
<b>5</b>	<b>Monitoring disease progression, treatment response and outcome</b>	<b>49</b>
	Joint count measures	49
	Laboratory measures	51
	Clinical measures	52

Radiographic measures	52
Criteria for remission of rheumatoid arthritis	52
Recommendations for monitoring treatment response	53
<b>6 Imaging techniques in rheumatoid arthritis</b>	<b>55</b>
What techniques are available?	55
Assessing radiographic progression	56
Joint abnormalities	57
Quantitative analysis of radiographs	61
<b>7 Guidelines</b>	<b>63</b>
EULAR guidelines	63
BSR guidelines	64
NICE guidance	65
<b>References</b>	<b>69</b>

## Author biography

Paul Emery is Arthritis Research Campaign Professor of Rheumatology and Head of the Academic Unit of Musculoskeletal Medicine at the University of Leeds, as well as Clinical Director (Rheumatology) at the Leeds Teaching Hospitals Trust in the United Kingdom. He graduated in medicine from the University of Cambridge and completed specialist accreditation in internal medicine and rheumatology. He completed his thesis on the immunopathology of rheumatoid arthritis at Guy's Hospital, and then served as Head of Rheumatology at the Walter and Eliza Hall Institute in Melbourne. He was senior lecturer in rheumatology at the University of Birmingham, UK from 1987–1995 until his present appointment.

Professor Emery has served as a member of several education committees including the Senior Advisory Committees of the Royal College of Physicians, the MRCP Part 1 Board. He is currently the President of EULAR, a past member of the Scientific Committee and Chairs the MRI imaging group. He has served on the editorial boards of several journals, including *Rheumatology*, *Arthritis and Rheumatism*, *Annals of the Rheumatic Diseases*, *Clinical and Experimental Rheumatology*, *Clinical Rheumatology* and *Modern Rheumatology (Japanese Rheumatology Association Journal)*.

He is a recipient of the Roche Biennial Award of Clinical Rheumatology, the Rheumatology Hospital Doctor of the Year award 1999 and the EULAR prize 2002 for outstanding contribution to Rheumatology research. Professor Emery's research interests centre around the immunopathogenesis and immunotherapy of rheumatoid arthritis and connective tissue diseases. He has a special interest in the factors leading to persistent inflammation. He has published over 650 peer-reviewed articles in this area.

## Rheumatoid arthritis: an overview

Rheumatoid arthritis is a chronic systemic inflammatory arthritis of auto-immune origin that affects primarily the synovial joints, usually in a symmetrical pattern. It is the most common and most serious of the inflammatory arthritides, and it dominates clinical rheumatological practice (Silman 2002). Current evidence shows that prompt diagnosis and early instigation of definitive disease-modifying treatment can delay or avoid progression and enable patients to retain function that would otherwise be lost in this progressive and frequently disabling disease.

### Incidence

Rheumatoid arthritis is estimated to affect between about 0.5 and 2% of the population worldwide (Alamanos and Drosos 2005, Emery 2006, Sommer et al. 2005).


Broadly speaking the disease is equally common worldwide, although there is some evidence of variation, with lower prevalence rates in southern Europe than in northern Europe and North America (Alamanos et al. 2006). There may also be lower rates in developing countries than in the developed world, a finding that has been attributed to environmental effects of urbanisation, although the precise causes are not known (Kalla and Tikly 2003). Some studies have reported a general trend for a decrease in frequency (Doran et al. 2002), more specifically in countries with high rates of disease (Alamanos et al. 2006) although such a trend is far from certain (Silman 2002). However, the small number of studies for most areas of the world and the lack of incidence studies for developing countries means that knowledge of the global epidemiology of rheumatoid arthritis is limited (Alamanos et al. 2006). UK data are summarised in Figure 1.1.

#### Rheumatoid arthritis in the UK

- 24 new cases of rheumatoid arthritis per 100,000 of the population per year <sup>a</sup>
- > 580,000 people have rheumatoid arthritis <sup>b</sup>
- Women 2–3 times more likely to be affected than men <sup>c</sup>

**Figure 1.1 Rheumatoid arthritis in the UK.** <sup>a</sup>Wiles et al. 1999, <sup>b</sup>National Audit Office 2009, <sup>c</sup>Symmons et al. 1994.





**Figure 1.2 Pathogenesis of early rheumatoid arthritis, involving genetic and environmental factors.** EBV, Epstein–Barr virus. Adapted from Pratt et al. 2009, with data from Pratt et al. 2009, Lee et al. 2007, Balandraud et al. 2004.

## Aetiology and pathophysiology

The precise aetiology of rheumatoid arthritis is not known but it is complex and multifactorial, and involves both genetic and environmental components (Lee et al. 2007) (Figure 1.2).

### Genetic factors

The disease is known to cluster in families, and those with a first-degree relation with rheumatoid arthritis are between two and 10 times more likely to have the disease than the general population (John et al. 1998). A genetic basis for this familial preponderance is confirmed by the observation that the concordance for rheumatoid arthritis in monozygotic twins is about 15%, up to five times the concordance in dizygotic twins (Pratt et al. 2009). Certain alleles at the human leukocyte antigen (HLA)-*DRB1* locus are known to be associated with susceptibility to rheumatoid arthritis and with the presence of autoantibodies, notably rheumatoid factor and antibodies against cyclic citrullinated peptide (anti-CCP antibodies or ACPA) (Gregersen et al. 1987). For example, *HLA-DRB1\*401* and *DRB1\*0404* are associated with radiographic erosions (Weyand et al. 1992).

Other genetic associations have also been identified (Pratt et al. 2009) (Figure 1.3). In Europeans, about 50% of genetic susceptibility to rheumatoid arthritis is contributed by two genes: *HLA-DRB1* and *PTPNN2* (Pratt et al. 2009).